Eli Lilly’s existing October 2024 research collaboration with Peptron grants only a non-exclusive license for internal R&D on SmartDepot’s sustained-release microsphere technology for peptides, with no commercial rights included. Recent reporting highlights Lilly’s pivot toward oral obesity candidates and monthly injectable alternatives, alongside the absence of any announced technology-transfer, milestone payments, or binding commercial terms in the intervening 22 months. With the October 7 resolution date roughly eight weeks away and no disclosed progress updates or regulatory filings indicating accelerated negotiations, traders assign just 12.5% implied probability to a surprise commercial licensing agreement materializing in time.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于13% 概率
$11,264 交易量
$11,264 交易量
2026-10-07
13% 概率
$11,264 交易量
$11,264 交易量
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 research collaboration with Peptron grants only a non-exclusive license for internal R&D on SmartDepot’s sustained-release microsphere technology for peptides, with no commercial rights included. Recent reporting highlights Lilly’s pivot toward oral obesity candidates and monthly injectable alternatives, alongside the absence of any announced technology-transfer, milestone payments, or binding commercial terms in the intervening 22 months. With the October 7 resolution date roughly eight weeks away and no disclosed progress updates or regulatory filings indicating accelerated negotiations, traders assign just 12.5% implied probability to a surprise commercial licensing agreement materializing in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市场开放时间： May 5, 2026, 8:02 PM ET
交易量
$11,264结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 research collaboration with Peptron grants only a non-exclusive license for internal R&D on SmartDepot’s sustained-release microsphere technology for peptides, with no commercial rights included. Recent reporting highlights Lilly’s pivot toward oral obesity candidates and monthly injectable alternatives, alongside the absence of any announced technology-transfer, milestone payments, or binding commercial terms in the intervening 22 months. With the October 7 resolution date roughly eight weeks away and no disclosed progress updates or regulatory filings indicating accelerated negotiations, traders assign just 12.5% implied probability to a surprise commercial licensing agreement materializing in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,264结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing October 2024 research collaboration with Peptron grants only a non-exclusive license for internal R&D on SmartDepot’s sustained-release microsphere technology for peptides, with no commercial rights included. Recent reporting highlights Lilly’s pivot toward oral obesity candidates and monthly injectable alternatives, alongside the absence of any announced technology-transfer, milestone payments, or binding commercial terms in the intervening 22 months. With the October 7 resolution date roughly eight weeks away and no disclosed progress updates or regulatory filings indicating accelerated negotiations, traders assign just 12.5% implied probability to a surprise commercial licensing agreement materializing in time.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题